David R. Liu
This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| David R. Liu | |
|---|---|
 | |
| Name | David R. Liu |
| Birth date | 1973 |
| Birth place | Boston, Massachusetts |
| Nationality | American |
| Fields | Chemistry, Biochemistry, Molecular biology, Genetics |
| Workplaces | Harvard University, Broad Institute, Merck, Genentech |
| Alma mater | Harvard University, California Institute of Technology |
| Doctoral advisor | Peter B. Dervan |
| Known for | Base editing, CRISPR evolution, directed evolution, protein engineering |
| Awards | MacArthur Fellows Program, National Academy of Sciences, Heineken Prize, Paul Marks Prize for Cancer Research |
David R. Liu is an American chemist and biochemist noted for pioneering methods in protein engineering and genome editing, particularly base editing and phage-assisted continuous evolution. He is a professor at Harvard University and a core institute member at the Broad Institute of MIT and Harvard, where his laboratory combines techniques from Chemistry, Molecular biology, and Genetics to develop molecular tools for biomedical research. His work has influenced academic research, biotechnology startups, and translational efforts involving institutions such as Genentech and Merck.
Early life and education
Born in Boston, Massachusetts, he attended Harvard University for undergraduate studies, where he studied Chemistry and related sciences before pursuing graduate research at the California Institute of Technology under the supervision of Peter B. Dervan. His doctoral work intersected with themes prominent in Organic chemistry and Chemical biology and placed him in the milieu of researchers associated with institutions like MIT and the University of California, Berkeley. After earning his Ph.D., he conducted postdoctoral research at Harvard Medical School and joined the faculty at Harvard University, affiliating with collaborative centers including the Broad Institute.
Research and career
His laboratory at Harvard University and membership at the Broad Institute situate him among investigators who bridge Chemistry and Molecular biology, working alongside groups from Stanford University, MIT, Caltech, and the Salk Institute. He has contributed to method development in directed evolution, enzyme engineering, and genome modification, engaging in collaborations with teams from Genentech, Novartis, Pfizer, and academic groups at Yale University and Princeton University. His career trajectory includes advisory and consultative roles for biotechnology companies and interactions with funding bodies such as the National Institutes of Health, the Howard Hughes Medical Institute, and international organizations that support scientific research.
Directed evolution and base editing
He is widely recognized for advances in directed evolution techniques, including phage-assisted continuous evolution (PACE), which links evolutionary selection to continuous propagation using bacteriophage systems related to work on Escherichia coli phage biology and methods established by labs at Caltech and MIT. PACE has been adopted by researchers at Stanford University, University of California, San Francisco, and pharmaceutical research centers at Roche and GlaxoSmithKline. Building on genome-editing platforms such as CRISPR-Cas9 and prior gene-targeting approaches from groups at J. Craig Venter Institute and Max Planck Society laboratories, his lab developed base editors—fusion proteins that enable targeted nucleotide conversions without double-strand DNA breaks. Base editing has been used by investigators at Broad Institute, University of Oxford, Cold Spring Harbor Laboratory, and clinical research teams at University College London and Johns Hopkins University. The technology interacts conceptually with prior work on zinc finger nucleases, TALENs, and adenine deaminase research from teams at University of Tokyo and Riken.
Entrepreneurship and commercialization
His inventions spurred the creation of biotechnology companies and partnerships, including startups and collaborations with venture-backed firms in the Cambridge, Massachusetts ecosystem, the San Francisco Bay Area, and international hubs such as Cambridge, UK and Shanghai. He has co-founded or advised companies that licensed base editing and directed evolution technologies, engaging with corporate partners like Novartis, Vertex Pharmaceuticals, Regeneron Pharmaceuticals, and academic spinouts linked to Harvard University and the Broad Institute. These commercialization activities involve intersections with investors and incubators such as Flagship Pioneering, Third Rock Ventures, and technology transfer offices at Harvard University and Massachusetts Institute of Technology.
Awards and honors
He has received numerous recognitions from scientific and philanthropic organizations, including the MacArthur Fellows Program "genius grant", election to the National Academy of Sciences, the Heineken Prize for biochemistry and biophysics, and the Paul Marks Prize for Cancer Research. His honors parallel awards given to contemporaries at institutions like Stanford University, MIT, Caltech, and the Salk Institute, and he has been acknowledged by societies such as the American Chemical Society, the American Association for the Advancement of Science, and international academies.
Selected publications and influence
His publications appear in high-profile journals and preprint platforms commonly used by researchers at Harvard University, Broad Institute, Stanford University, and Caltech, including landmark papers describing PACE, base editing, and methodological innovations in journals frequented by investigators at Nature, Science, Cell, and specialized periodicals connected to Nature Methods and Proceedings of the National Academy of Sciences. His work is widely cited by teams at University of California, Berkeley, ETH Zurich, Imperial College London, and translational groups at Massachusetts General Hospital and Brigham and Women’s Hospital. Beyond primary research articles, his influence extends through patents assigned or licensed by institutional technology transfer offices and through training of postdoctoral fellows and students who have joined faculties at institutions including Yale University, Princeton University, University of Pennsylvania, and companies in the biotechnology sector.
Category:American chemists Category:Harvard University faculty